INTRODUCTION
The course of renal cancer is highly unpredictable. Patients with small tumor may have distant metastasis with adverse prognosis, while patients with metastasis to lymph nodes, after nephrectomy may live more than five years [1, 2] . In numerous studies over last decade, new clinicopathological features expected to support prognostication in various groups of patients with RCC (i.e. before or after treatment, with or without metastatic disease) were considered [3] . Among them some clinical (symptoms, performance status), histological (tumor subtype, histological grade, microvascular invasion), biochemical (hemoglobin, calcium concentrations, LD serum activity), molecular, and cytogenetic variables turned out to provide additional prognostic information, as they correlate with long term follow-up outcomes reported in previously performed studies [4, 5, 6] . Based on these data, and independent prognostic factors (IPFs), new scoring systems assessing the clinical course of renal cancer were proposed [7] . Among the variety of major scoring systems referring to renal cancer, it is remarkable how different sets of IPFs they may use, depending on aspects of O r i g i n a l P a P E r
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Prognostic factors of overall survival in renal cancer patients -single oncological center study , Jacek Jakubowski 1 a prognosis they are about to assess and groups of patients they apply to. For instance Karakiewicz nomogram (KN) predicts 1-, 2-, 5-, and 10-year of cancer specific survival for the patients with renal cancer in all stages. This post-surgery nomogram uses as IPFs: TNM classification (2002), tumor size, tumor grade according to Fuhrman, histological tumor sub-type, patient's age, and presence of symptoms [8] . Another scoring system, assessing overall survival of the patients with metastatic renal cancer disease was proposed by Motzer. The IPFs set according to this model included: Karnofsky performance status, hemoglobin concentration, serum calcium concentration, serum lactate dehydrogenase activity (LDH), and time passed from diagnosis to treatment [9] . One of the merits of the current prognostic tools is the fact that their efficacy is measurable. It is expressed by prediction accuracy (PA), a value that falls within the range from 100% (an ideal confidence of the prediction) to 50% (what represents the outcome probability assessment equal to a toss of a coin) [3] . This allows to compare scoring systems to one another and to evaluate their prognostic efficacy for different populations (external validation). It is stressed in the literature that the discriminating ability of a particular scoring systems vary among populations, depending on ethnic dissimilarities and quality of treatment (diagnostic and therapeutic standards functioning in local healthcare system, i.e. methods of histopathological examination, agents available in adjuvant therapy) [10] [11] [12] [13] [14] . It is necessary to confirm the usefulness of the IPFs defined previously and prognostic tools in various populations of patients [3, 15] .
MATERIAL AND METHOD
Retrospective analysis of 148 patients with renal cancer, treated at the Oncological Institute in Krakow in years 2000-2007, was performed. Mean age of the analyzed group of patients was 59.6 years (range: 33 to 79), mean observation time was 51 months (range 5 to 109 months). Staging (according to TNM scale, version for the year 2002) was estimated based on computer tomography with contrast and lung radiogram [16] . Basing on the same clinical data, the patients were divided according to anatomic stages (TNM grouping according to AJCC, 2010). In case of suspicion of metastasis to bones or the central nervous system, additional imaging studies were performed. Kidney removal was performed according to standard criteria and was accompanied by local lymphadenectomy, if they were palpable during surgery or enlarged in imaging studies. After surgery, patients were followed up no less than every 
Statistical analysis
Continuous quantitative variables were characterized using arithmetic mean, median, range, and standard deviation. Categorical variables were reported as proportions expressed in percentages. Patients were divided into cohorts in respect to each variable. The cumulative overall survival rates in subsequent years of follow-up were calculated for the entire group and for each cohort separately. In the same way, the Kaplan-Meier cumulative survival probability curves were plotted. In the univariate analysis, using log-rank test, differences in overall survival between cohorts and their statistical significances were assessed. Factors influencing overall survival were included in multivariate Cox regression analysis, which gave final identification of independent prognostic factors in the analyzed group of patients. Basic statistical significance level used in the paper was p <0.05. The characteristics of the analyzed group are presented in table 1 .
RESULTS
The 1, 2, 3, 4, and 5-year cumulative survival probability in the entire group of patients was 58.8%, 38.2%, 32.7%, 29.1%, and 21.4%, respectively. Our study comprised patients with RCC in all stages. However, the majority of them (89.9%) were metastatic. Most of the patients in our group died due to the cancer, and cancer specific and overall survival did not significantly change in value. All clinicopathological and biochemical data were evaluated for their influence on overall survival (OS). There were no differences in survival rates in respect to sex (5-year survival: F-19.8%, M-27.1% p = 0.3068), whereas analysis of age distribution by the use "kmean" method revealed two points of highest morbidity: 51.5 and 69 years.
Results of univariate analysis describing the influence of each variable on overall survival in our group of patients were gathered in tables 2, 3, 4, and 5. Selected factors were also presented as Kaplan Meier curves.
Univariate analysis
Prognostic factors from history and physical examination (Table 2) . Prognostic factors from imaging (Table 3) Comparing survival rates in groups subdivided according to TNM features and AJCC tumor stages (2010) substantial differences in overall survival rates were found (p <0.001) ( Prognostic factors from histological examination (Table 4 
Multivariate Cox regression analysis
The group of clinical, histopathological and biochemical data mentioned above were analyzed using multivariate Cox regression model with the aim of distinguishing independent factors of the overall survival prediction in a given population of patients with renal cancer. This analysis showed independent prognostic value of each particular factor in overall survival assessment and their usefulness. In the univariate analysis performance status expressed in Karnofsky scale and gammaglutamylotranspeptidase activity (GGTP) also appeared to have prognostic value; providing, however, that other variables were constant (Table 6 ).
Multivariate Cox model analysis revealed that several previously described factors had a statistically significant, independent influence on overall survival. The set of identified independent prognostic factors (IPFs) of overall survival (at p <0.05) consisted of performance status, smoking history, hemoglobin concentration, AJCC anatomical staging, tumor grade, and presence of microvascular invasion. Presented data confirmed substantially longer survival rates of patients after surgery and indicated that nephrectomy is also an independent prognostic factor (p <0.02) ( Table 7) . [20, 21] .
DISCUSSION
In the epidemiology of renal cancer, smoking is a well-documented risk factor of morbidity [22] . It is also an IPF of CCS in several other cancers, i.e. colon, bladder [23, 24] . However, information regarding its influence on survival in RCC is poor. Recently, researchers from UCLA published an extensive work describing the negative impact of smoking on clinicopathological features and survival outcomes in an investigated group of 802 patients with RCC [25] .
There was a significant difference in distribution of adverse clinicopathological features (ECOG PS, severity of comorbidities, tumor extent, vascular invasion) with higher incidence in the smoking group. The analysis also showed the correlation between smoking history and frequency of p53 suppressor gene mutation, and confirmed p53 overexpression to be IPF of CCS in all patients. Multivariate analysis revealed smoking history to be IPF, both of CCS and OS in localized RCC, however, these results were not confirmed in the group of patients with metastatic disease. In our study, smoking history was an IPF of OS with HR ratio 3.27. Serum hemoglobin was also found be an IPF of OS in our group. Anemia is a common finding in patients with cancer disease. In 2001 Caro et al. published a systemic quantitative review of 60 studies describing the role of anemia in various types of neoplasms [26] . In this review about 33% of patients were anemic and their median survival was decreased by 20-43%. Statistical analysis revealed a low hemoglobin level to be a negative predictor of OS, and the highest HRs were observed in cases of multiple myeloma and lymphoma (4.47 and 3.74, respectively). In anemic patients with RCC, HR was 1.9. The authors also highlighted controversies about the hemoglobin level cut-off value, which ranged from 8.5 g/dl to 14 g/dl, and the unclear link between anemia and tumor progression (apart from malignancies affecting bone marrow and other reticuloendothelial sites). In renal cancer, anemia is considered to result from elevated levels of inflammatory cytokines and increased catabolism induced by the tumor. However, in metastatic patients it may also be caused by systemic therapies administered to them. Some prognostic models stratifying risk in metastatic patients qualified to immune or targeted therapies use a low hemoglobin level as a negative predictor (Motzer, Negrier, Manola) [19, 27, 28] . In renal cancer, as well as in most of neoplasms, tumor involvement is the basic and most crucial prognostic factor predicting the course of disease. The first formal scale assessing the anatomical advancement of renal cancer correlating with OS was proposed by Robson. In 1978, however, it was replaced by the TNM classification involving consensus of US experts associated with the Union Against Cancer and the American Joint Committee. AJCC anatomic stages categorize patients with particular constellations of TNM features in respect to substantial interferences with distant outcomes, which can also vary depending on clinical situation [2, 29] . For instance, 5-year cancer-specific survival in patients who underwent surgical procedure range from 90-95% for stage I, 75-85% for stage II, 60-70% for stage III, and 20-30% for stage IV [30, 31] . Overall survival regardless of intervention, estimated in over 3,700,000 cancer cases was recorded in the National Cancer Data Base (NCDB) as 84.7%, 82.9%, 59.8%, and 11.1% for 1st, 2nd, 3rd, and 4th stages, respectively (Analysis from year 2000) [32, 33] . These data show that the presence of systemic metastases results in the highest reduction in survival rates. Nodal involvement is also associated with substantial decrease in survival. Surgical treatment significantly increases overall survival regardless of disease advancement. These finding correspond with our results. Tumor grade, next to TNM, is an approved independent prognostic factor included in several major nomograms (Frank, Karakiewicz, Zissmann) [16, 20, 31, 34] . Similar results were observed in our group. Another histological finding affecting RCC prognosis is presence of microvascular invasion. Klatte et al., analyzing cancer specific survival in 258 patients with papillary renal cancer confirmed the usefulness of this prognostic factor, and the nomogram he proposed is one of the highest prediction accuracy (94%) [35] . In our work, 2-and 5-year patients' overall survival, in dependence to the presence of MVI, was [3, 37] . None of the scoring systems have been validated for the Polish population. Polish clinicians just have to assume that foreign prognostic models are applicable to assess outcomes in their patients. This lack of certainty, apart from doubts in their additional value, is one of reasons discouraging clinicians from using scoring systems in RCC prognostication in Poland.
We believe that Polish population deserves adequate validations of modern prognostic models and evaluation of IPFs of RCC progression.
